Corporate Profile KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs. Minimum 15 minutes delayed. Source: LSEG View All Stock Information All Stock Information
KalVista, a Company of the Chiesi Group, Reinforces Its Commitment to the Hereditary Angioedema (HAE) Community with New Real-World and Clinical Research Presented at the ACAAI Annual Meeting Nov 12, 2026
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema May 28, 2026
